Canada Life’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.08M | Sell |
76,342
-5,536
| -7% | -$207K | 0.01% | 974 |
|
|
2025
Q4 | $2.85M | Sell |
81,878
-16,181
| -17% | -$1.27M | 0.01% | 1011 |
|
|
2025
Q3 | $8.21M | Buy |
98,059
+460
| +0.5% | +$33.3K | 0.01% | 629 |
|
|
2025
Q2 | $7.17M | Sell |
97,599
-7,443
| -7% | -$540K | 0.01% | 650 |
|
|
2025
Q1 | $12M | Buy |
105,042
+308
| +0.3% | +$18.7K | 0.02% | 516 |
|
|
2024
Q4 | $5.27M | Buy |
104,734
+15,838
| +18% | +$830K | 0.01% | 809 |
|
|
2024
Q3 | $4.12M | Sell |
88,896
-3,198
| -3% | -$114K | 0.01% | 972 |
|
|
2024
Q2 | $2.99M | Buy |
92,094
+13,107
| +17% | +$359K | 0.01% | 1084 |
|
|
2024
Q1 | $1.99M | Sell |
78,987
-12,982
| -14% | -$307K | ﹤0.01% | 1260 |
|
|
2023
Q4 | $2.98M | Sell |
91,969
-1,179
| -1% | -$32.4K | 0.01% | 1038 |
|
|
2023
Q3 | $2.54M | Buy |
93,148
+2,488
| +3% | +$72K | 0.01% | 1068 |
|
|
2023
Q2 | $2.02M | Sell |
90,660
-10,281
| -10% | -$237K | ﹤0.01% | 1196 |
|
|
2023
Q1 | $2.18M | Sell |
100,941
-24,266
| -19% | -$532K | 0.01% | 1188 |
|
|
2022
Q4 | $2.55M | Buy |
125,207
+18,524
| +17% | +$464K | 0.01% | 1105 |
|
|
2022
Q3 | $2.73M | Buy |
106,683
+11,972
| +13% | +$320K | 0.01% | 995 |
|
|
2022
Q2 | $2.25M | Buy |
94,711
+12,443
| +15% | +$271K | 0.01% | 1108 |
|
|
2022
Q1 | $1.9M | Buy |
82,268
+118
| +0.1% | +$2.51K | ﹤0.01% | 1224 |
|
|
2021
Q4 | $1.63M | Sell |
82,150
-10,175
| -11% | -$206K | ﹤0.01% | 1308 |
|
|
2021
Q3 | $1.83M | Buy |
92,325
+1,896
| +2% | +$39.7K | ﹤0.01% | 1235 |
|
|
2021
Q2 | $1.99M | Hold |
90,429
| – | – | ﹤0.01% | 1155 |
|
|
2021
Q1 | $2.15M | Sell |
90,429
-11,939
| -12% | -$319K | 0.01% | 1100 |
|
|
2020
Q4 | $2.68M | Sell |
102,368
-13,013
| -11% | -$274K | 0.01% | 989 |
|
|
2020
Q3 | $2.01M | Sell |
115,381
-12,383
| -10% | -$197K | ﹤0.01% | 1055 |
|
|
2020
Q2 | $2.15M | Sell |
127,764
-8,749
| -6% | -$123K | ﹤0.01% | 1030 |
|
|
2020
Q1 | $1.62M | Buy |
136,513
+8,628
| +7% | +$107K | ﹤0.01% | 1058 |
|
|
2019
Q4 | $1.53M | Buy |
+127,885
| New | +$1.78M | ﹤0.01% | 1284 |
|
|
2019
Q3 | – | Sell |
-139,501
| Closed | -$1.55M | – | 1373 |
|
|
2019
Q2 | $1.55M | Hold |
139,501
| – | – | ﹤0.01% | 1319 |
|
|
2019
Q1 | $1.64M | Hold |
139,501
| – | – | ﹤0.01% | 1160 |
|
|
2018
Q4 | $1.72M | Buy |
139,501
+12,335
| +10% | +$163K | ﹤0.01% | 1104 |
|
|
2018
Q3 | $1.78M | Buy |
127,166
+4,413
| +4% | +$61.7K | ﹤0.01% | 1241 |
|
|
2018
Q2 | $1.93M | Hold |
122,753
| – | – | ﹤0.01% | 1204 |
|
|
2018
Q1 | $2.02M | Buy |
122,753
+4,699
| +4% | +$87.1K | ﹤0.01% | 1146 |
|
|
2017
Q4 | $2.13M | Buy |
118,054
+110,442
| +1,451% | +$2M | 0.01% | 1134 |
|
|
2017
Q3 | $144K | Hold |
7,612
| – | – | ﹤0.01% | 2044 |
|
|
2017
Q2 | $90K | Hold |
7,612
| – | – | ﹤0.01% | 2148 |
|
|
2017
Q1 | $83K | Hold |
7,612
| – | – | ﹤0.01% | 2165 |
|
|
2016
Q4 | $55K | Sell |
7,612
-8,900
| -54% | -$69.7K | ﹤0.01% | 2298 |
|
|
2016
Q3 | $107K | Hold |
16,512
| – | – | ﹤0.01% | 2106 |
|
|
2016
Q2 | $90K | Buy |
+16,512
| New | +$85.9K | ﹤0.01% | 2135 |
|
Other funds holding CORT
ISL
VPM
VCM
PA
Canada Life's CORT Position: Q1 2026 in Review
Canada Life reduced its Corcept Therapeutics (CORT) stake by 6.8% in Q1 2026, selling an estimated $207K and leaving 76,342 shares worth $3.08M. The position accounts for 0.01% of the portfolio, ranked #974.
Canada Life first reported a position in CORT in Q2 2016 and has held it in 39 quarters since. The position peaked at $12M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.
- Canada Life held 76,342 shares of Corcept Therapeutics worth $3.08M as of Q1 2026.
- Canada Life sold 5,536 Corcept Therapeutics shares in Q1 2026, an estimated $207K.
- Corcept Therapeutics made up 0.01% of Canada Life's portfolio in Q1 2026, its #974 holding.
- Canada Life first reported a position in Corcept Therapeutics in Q2 2016 and has held it in 39 quarters since.
- Canada Life's Corcept Therapeutics position peaked at $12M in Q1 2025.
- 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.
Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.